1. Signaling Pathways
  2. GPCR/G Protein
  3. P2Y Receptor
  4. P2Y12 Receptor Isoform

P2Y12 Receptor

 

P2Y12 Receptor Related Products (22):

Cat. No. Product Name Effect Purity
  • HY-10064
    Ticagrelor
    Antagonist 99.98%
    Ticagrelor (AZD6140) is a reversible oral P2Y12 receptor antagonist for the treatment of platelet aggregation.
  • HY-15283
    Clopidogrel
    Inhibitor 99.57%
    Clopidogrel is an orally active platelet inhibitor that targets P2Y12 receptor. Clopidogrel is used to inhibit blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease.
  • HY-19638A
    Cangrelor tetrasodium
    Antagonist 99.93%
    Cangrelor tetrasodium, an adenosine triphosphate analogue, is a reversible and selective platelet P2Y12 antagonist, with prompt and potent antiplatelet effects. Cangrelor tetrasodium directly blocks adenosine diphosphate (ADP)-induced activation and aggregation of platelets. Cangrelor tetrasodium is also a nonspecific GPR17 antagonist.
  • HY-17459
    Clopidogrel hydrogen sulfate
    Inhibitor 99.43%
    Clopidogrel hydrogen sulfate is an antiplatelet agent to prevent blood clots. Clopidogrel hydrogen sulfate inhibits CYP2B6 and CYP2C19 with IC50s of 18.2 nM and 524 nM, respectively. Clopidogrel hydrogen sulfate is a potent antithrombotic agent that inhibits ADP-induced platelet aggregation.Clopidogrel hydrogen sulfate also is an orally active P2Y(12) inhibitor.
  • HY-108660
    PSB-0739
    Antagonist ≥98.0%
    PSB-0739 is a high-affinity potent, competitive, nonselective platelet P2Y12 receptor antagonist with a Ki values of 24.9 nM. The P2Y12 receptor plays a crucial role in platelet aggregation. Antithrombotic effect.
  • HY-161727
    P2Y14R antagonist 1
    Antagonist
    P2Y14R antagonist 1 (compound I-17) is a selective P2Y14R antagonist with an IC50 of 0.6 nM. It exhibits potent P2Y14R antagonistic activity, both in vitro and in vivo efficacy, and favorable pharmacokinetic profiles. P2Y14R antagonist 1 reduces the release of inflammatory factors and cell pyroptosis through the NOD-like receptor family pyrin domain-containing 3 (NLRP3)/gasdermin D (GSDMD) signaling pathway. P2Y14R antagonist 1 holds promise for research in the field of acute gouty arthritis.
  • HY-108648A
    2-MeSADP
    Agonist
    2-MeSADP (2-Methylthioadenosine diphosphate; 2-Methylthio-ADP) is a potent purinergic P2Y receptors agonist, with EC50s of 19, 6.2, and 5 nM for human P2Y13, mouse P2Y13 and human P2Y12, respectively. 2-MeSADP has pEC50s of 8.29 and 5.75 for human P2Y1 and rat P2Y6, respectively. 2-MeSADP induces platelet aggregation and shape change, and inhibits cyclic AMP accumulation in platelets exposed to prostaglandin E1.
  • HY-15284
    Prasugrel
    Inhibitor 99.85%
    Prasugrel (PCR 4099), a thienopyridine and proagent, inhibits platelet function. Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation.
  • HY-125989
    2-Methylthio-AMP
    Antagonist 98.94%
    2-Methylthio-AMP (2-MeSAMP) is a selective and direct P2Y12 antagonist. 2-Methylthio-AMP is an inhibitor of ADP-dependent platelet aggregation.
  • HY-15284A
    Prasugrel hydrochloride
    Inhibitor 98.90%
    Prasugrel hydrochloride (PCR 4099 hydrochloride), a thienopyridine and proagent, inhibits platelet function. Prasugrel hydrochloride is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation.
  • HY-15876
    Clopidogrel thiolactone
    Inhibitor ≥98.0%
    Clopidogrel thiolactone is an important intermediate in the metabolism of clopidogrel (HY-15283). Clopidogrel thiolactone has antiplatelet aggregatione effects. Clopidogrel is a P2Y12 receptor inhibitor that exerts antiplatelet effects.
  • HY-108648
    2-MeS-ADP trisodium
    Agonist 98.70%
    2-Methylthioadenosine diphosphate trisodium is a potent purinergic P2Y receptors agonist, with EC50s of 19, 6.2, and 5 nM for human P2Y13, mouse P2Y13 and human P2Y12, respectively. 2-Methylthioadenosine diphosphate trisodium has pEC50s of 8.29 and 5.75 for human P2Y1 and rat P2Y6, respectively. 2-Methylthioadenosine diphosphate trisodium induces platelet aggregation and shape change, and inhibits cyclic AMP accumulation in platelets exposed to prostaglandin E1.
  • HY-15799
    AZD1283
    Antagonist 99.33%
    AZD1283 is a potent P2Y12 receptor antagonist with a binding IC50 of 11 nM and a GTPγS IC50 of 25 nM. AZD1283 has excellent antiplatelet aggregation potency. AZD1283 can be used to research thromboembolic disorders.
  • HY-134353B
    ADP-β-S trilithium
    Activator
    ADP-β-S trilithium is the trilithium salt form of ADP-β-S (HY-134353). ADP-β-S trilithium is the activator for P2Y12 receptor, which upregulates levels of IL-1βand IL-6 production in microglial cells, promotes the phosphorylation and nuclear translocation of NF-κB, and enhances the activation of the NLRP3 inflammasome.
  • HY-15284S1
    Prasugrel-d3
    Inhibitor 98.58%
    Prasugrel-d3 is the deuterium labeled Prasugrel. Prasugrel (PCR 4099), a thienopyridine and proagent, inhibits platelet function. Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation[1].
  • HY-125989B
    2-Methylthio-AMP diTEA
    Antagonist ≥98.0%
    2-Methylthio-AMP (2-MeSAMP) diTEA is a selective and direct P2Y12 antagonist. 2-Methylthio-AMP diTEA is an inhibitor of ADP-dependent platelet aggregation.
  • HY-19638
    Cangrelor
    Antagonist
    Cangrelor (AR-C69931MX), an adenosine triphosphate analogue, is an intravenous, reversible and selective platelet P2Y12 antagonist, with prompt and potent antiplatelet effects. Cangrelor directly blocks adenosine diphosphate (ADP)-induced activation and aggregation of platelets. Cangrelor is also a nonspecific GPR17 antagonist.
  • HY-15284S
    Prasugrel-d5
    Inhibitor
    Prasugrel-d5 is deuterium labeled Prasugrel. Prasugrel (PCR 4099), a thienopyridine and prodrug, inhibits platelet function. Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation[1].
  • HY-123490
    Regrelor disodium
    Antagonist
    Regrelor disodium (INS 50589) is a platelet P2Y12 receptor antagonist. Regrelor disodium is a well-tolerated, reversible ADP competitive antagonist. Regrelor disodium inhibits cell proliferation. Regrelor disodium can be used in inflammation-related research.
  • HY-10064S
    Ticagrelor-d7
    Antagonist
    Ticagrelor-d7 is the deuterium labeled Ticagrelor. Ticagrelor (AZD6140) is a reversible oral P2Y12 receptor antagonist for the treatment of platelet aggregation[1][2].